Effect of Memantine on Prolonging Safe Driving in Early AD: a Pilot Study.
Can Geriatr J
; 24(4): 292-296, 2021 Dec.
Article
en En
| MEDLINE
| ID: mdl-34912482
BACKGROUND: To determine the feasibility of conducting an RCT on the potential effectiveness of memantine hydrochloride in prolonging safe driving in mild AD. METHODS: A placebo-controlled, double blind randomized trial was conducted. Forty-three individuals ≥60 with mild AD met screening criteria and were randomized. Driving ability was measured by a standardized on-road driving test. Outcomes were driving capacity at 6 and 12 months and completion of the 12-month intervention. RESULTS: Of 43 participants randomized, 59% of the memantine group and 52% of the placebo group completed the on-road test at 12 months (p = .66). All 13 memantine group participants maintained their driving status at 12 months, whereas only 8 of the 11 placebo group participants did (p = .040, OR = 4.45). CONCLUSIONS: Results provide the framework for designing a rigorous multisite clinical trial of memantine effect on maintaining driving capacity in mild AD.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
Idioma:
En
Revista:
Can Geriatr J
Año:
2021
Tipo del documento:
Article
Pais de publicación:
Canadá